Funding for this research was provided by:
Received: 26 January 2021
Accepted: 21 May 2021
First Online: 2 July 2021
: This study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the Ethics Committees at each participating centre.
: Not applicable.
: IAR has received grants by Daiichi-Sankyo, Biogen and Lilly. LPL has received grants by Daiichi-Sankyo and Biogen. JLB has received grants by Daiichi-Sankyo, Biogen, Lilly. EP has served on an advisory board for Takeda, Amgen, Daiichi Sankyo, Lilly, Eusa Pharma, and Deciphera, has received other research support from Bristol Myers Squibb, Pfizer, PharmaMar, and Daiichi Sankyo, and travel support from Lilly, PharmaMar, Takeda. AL reports institutional education grants by Johnson & Johnson, Alphamed, Globus, and Implantec. MvS reports institutional grants by Daiichi-Sankyo. YX, LP, and FE are employees of Daiichi-Sankyo.